Rituximab as a trigger factor of medication-related osteonecrosis of the jaw. A case report - Archive ouverte HAL Access content directly
Journal Articles Journal of Stomatology, Oral and Maxillofacial Surgery Year : 2020

Rituximab as a trigger factor of medication-related osteonecrosis of the jaw. A case report

, (1) , , , , , , (1)
1
M-J Javelot
  • Function : Author
S Agbo-Godeau
  • Function : Author
F Levy-Weil
  • Function : Author
S Laurence
  • Function : Author
P Goudot
  • Function : Author
  • PersonId : 928297
R-H Khonsari

Abstract

Rituximab, an anti-CD20 monoclonal antibody, is an effective treatment for rheumatoid arthritis. Here we report the case of a patient with rheumatoid arthritis, having taken risedronate for 14 months to prevent corticosteroid-induced osteoporosis, more than 2 years ago, who presented osteonecrosis of jaw following herpetic gingivostomatitis two weeks after the beginning of a rituximab treatment associated with her usual anti-rheumatic drugs. Eight weeks later, no bone and/or gum healing was observed and a stage 2 medication-related osteonecrosis of the jaw (MRONJ) was diagnosed. A conservative approach was decided with antiseptic mouth washes, low-level laser treatment (LLLT) and systemic therapy with teriparatide. Complete mucosal coverage was obtained after more two years of follow-up. We suggest that rituximab as immunosuppressant might be a cause or a decompensating factor of MRONJ. Non- surgical periodontal treatment with LLLT and teriparatide are candidates for the treatment of MRONJ.
Not file

Dates and versions

hal-03579089 , version 1 (17-02-2022)

Identifiers

Cite

M-J Javelot, Johan Sergheraert, S Agbo-Godeau, F Levy-Weil, S Laurence, et al.. Rituximab as a trigger factor of medication-related osteonecrosis of the jaw. A case report. Journal of Stomatology, Oral and Maxillofacial Surgery, 2020, 121, pp.300 - 304. ⟨10.1016/j.jormas.2019.06.009⟩. ⟨hal-03579089⟩

Collections

URCA BIOS
10 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More